Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept plus prednisone vs prednisone in IgA nephropathy
ChiCTR2300076949Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Nov 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of telitacicept in IgA nephropathy (IgAN) (2 arms), sponsored by Xijing Hospital. Primary endpoint: 24-hour urine protein. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2300076949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076949.